Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development Overview
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEW
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEW
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEW
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSIn the realm of public health and clinical practice, the selection and application of screening tools are pivotal decisions that have far-reaching implications. Recent discussions have shed light on the nuanced challenges associated with race-based screening tools, particularly in the context of obesity (1-3). These challenges are not about rejecting the use of race in healthcare algorithms outright but rather about critically evaluating how tools like BMI are utilized and the broader implications they carry for health equity.
This post aims to explore the nuanced implications of obesity screening tools, with a focus on understanding the context of their use to ensure equitable healthcare practices.
The Body Mass Index (BMI) is a widely used tool for assessing obesity, yet its application in diverse populations brings to the fore complex issues of equity and accuracy. While BMI can offer a quick reference point for health assessment, its utility is limited by its inability to account for muscle mass, bone density, and racial and ethnic variations in body composition. This limitation becomes particularly pronounced when BMI is used as a standalone metric for health risks in racially and ethnically diverse populations.
The critique of race-based screening tools, such as differential BMI thresholds, is rooted in a deep concern for their potential to exacerbate healthcare disparities (4). These tools, when applied without a comprehensive understanding of the individual and collective factors that influence health, may inadvertently perpetuate a cycle of inequity. For instance, the application of a universal BMI standard across all racial and ethnic groups overlooks the nuanced differences in body composition and the distribution of adipose tissue, leading to potential misclassification and the overlooking of at-risk individuals.
In the quest to improve obesity screening and overcome the limitations of traditional measures like BMI, healthcare professionals have turned to alternative methods that offer a more nuanced view of body composition. One of the most promising of these methods is the Dual-Energy X-ray Absorptiometry (DEXA) scan (5). DEXA scans are known for their precision in measuring body fat percentage, lean muscle mass, and bone density, providing a comprehensive overview of an individual's health status. Unlike BMI, which does not differentiate between fat and muscle, DEXA scans can accurately assess visceral fat—the type of fat associated with a higher risk of chronic diseases, including Type 2 Diabetes and heart disease.
Similarly, Bioelectrical Impedance Analysis (BIA) and Magnetic Resonance Imaging (MRI) are other sophisticated technologies that offer detailed insights into body composition and the distribution of adipose tissue (6-7). These methods can reveal the amount of visceral fat and ectopic fat, crucial indicators of metabolic health not visible through traditional screening methods.
Despite their advantages, the adoption of DEXA scans, MRI, and BIA as standard obesity screening tools faces significant barriers. The primary challenge is the cost: the equipment required for these tests is expensive to purchase and maintain, making them less accessible for many healthcare providers, especially those in primary care and peripheral settings. Additionally, the complexity of these tests requires specialized training for healthcare professionals, further limiting their widespread use. Studies have shown that 88% of the US population do not have access to DXA scans (8).
Another significant hurdle is practicality. Unlike BMI calculation, which can be quickly and easily performed in any clinical setting without specialized equipment, DEXA scans and MRI require specific facilities and considerably more time for both the test and the interpretation of results. This makes them impractical for screening large populations or for use in settings with limited resources.
Furthermore, while these advanced methods provide valuable insights for individualized care plans, their cost-effectiveness at a population level is still under debate. The healthcare system must balance the benefits of these precise measurements against the practical considerations of accessibility, cost, and the need for widespread screening capabilities.
The "Screen at 23" Initiative: A Case Study in Equity and Policy (9)
The challenge, therefore, is not merely about the tool itself but about the context in which it is employed. It raises critical questions about how we can refine our screening practices to ensure they are both effective and equitable. How do we leverage the data and tools at our disposal while remaining cognizant of their limitations and the diverse realities of the populations we serve?
The "Screen at 23" program serves as a pioneering example of how targeted health initiatives can lead to more equitable health outcomes. Recognizing that Asian Americans are at a higher risk of cardiometabolic diseases at lower BMI thresholds than the general population, this initiative sought to redefine the BMI cutoff for diabetes screening for this group. The traditional BMI threshold of 25 kg/m^2 did not accurately reflect the health risks faced by Asian Americans, prompting the need for a more inclusive and representative guideline.
This program was not merely a change in numerical values; it was a comprehensive effort to align health screening practices with the real-world diversity of population health. By lowering the BMI cutoff to 23 kg/m^2 for Asian Americans, the initiative aimed to improve early detection and intervention for diabetes, ultimately preventing long-term complications and reducing the burden of chronic disease in this population.
The "Screen at 23" initiative underscores the importance of not just seeking better tools for health assessment but also advocating for policies and guidelines that reflect the nuanced realities of diverse populations. It demonstrates that effective healthcare requires a dual approach: embracing technological advancements for precise health assessment and ensuring that health policies are informed by a deep understanding of cultural, ethnic, and physiological differences.
The success of the "Screen at 23" program is a testament to the power of community advocacy, research, and policy-making coming together to challenge and redefine the norms of health screening. It highlights the necessity of continuous dialogue among healthcare providers, researchers, policy-makers, and communities to identify and address disparities in health outcomes.
As we continue to explore and refine alternative methods for obesity screening, the goal remains clear: to develop accessible, cost-effective tools that can accurately assess and manage the risks associated with obesity. Addressing these concerns requires a multifaceted strategy that goes beyond the binary of using or not using race-based data. It calls for a nuanced approach to health screening that:
The journey towards health equity is multifaceted, involving the intricate balance of innovation, policy, and community engagement. The "Screen at 23" initiative exemplifies how targeted efforts can lead to significant improvements in health outcomes for at-risk populations. By adopting a more inclusive and context-aware approach to screening, we can move toward a healthcare system that recognizes and respects the diversity of human health. This approach not only aims to improve the accuracy of health assessments but also to ensure that our efforts to manage and prevent conditions like obesity are grounded in principles of equity and compassion.
Through careful consideration of the tools we use and the contexts in which we apply them, we can work toward narrowing health disparities and building a healthcare environment that serves all individuals with the attention and care they deserve.
References:
See how observational health data sciences and informatics (OHDSI), a research collaborative with a global footprint, can expand data access and reduce cost of ownership.
